津药药业（600488.SH）1月16日在投资者互动平台表示，公司在欧盟地区的原料药业务覆盖多个主要 欧盟国家，外销业务主要由控股子公司天发药业进出口有限公司负责。目前，公司该区域业务年营业收 入在公司整体营业收入中占比较小。未来，公司将持续关注海外市场机遇，结合自身业务发展规划与市 场需求，加强产品海外注册、拓展海外业务，增强企业全球竞争力。 每经AI快讯，有投资者在投资者互动平台提问：请问公司近年是否存在向欧盟出口或销售的相关业 务？如有，欧盟地区业务收入在公司整体营业收入中的占比大致为多少？此外，公司对欧盟市场的销售 主要通过哪种方式实现？是以境内主体直接向欧盟客户出口为主，还是通过在欧盟国家设立的子公司进 行销售，或通过第三方贸易商、代理商转销至欧盟市场？ （文章来源：每日经济新闻） ...

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its modified new drug LH-2417, aimed at treating benign prostatic hyperplasia in men [2] Group 1: Company Developments - Lianhuan Pharmaceutical announced the approval of the clinical trial for LH-2417, which is intended for the initial treatment of symptoms associated with benign prostatic hyperplasia [2] - The company has invested approximately 1.3678 million yuan in the research and development of this drug [2] - Due to the lengthy development cycle and potential uncertainties associated with modified new drugs, it is expected that there will be no significant impact on the company's revenue and operating performance in the short term [2]

Group 1 - Eddie Pharmaceuticals' stock price increased by 5.15% on January 16, reaching 22.06 CNY per share, with a trading volume of 520 million CNY and a turnover rate of 6.05%, resulting in a total market capitalization of 9.282 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 24.14% during this period [1] - The company, established on December 15, 2009, and listed on July 20, 2020, focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products, with revenue composition as follows: human-derived proteins 41.11%, new drugs 35.69%, diagnostic equipment and reagents 13.62%, generic drugs 9.47%, and others 0.11% [1] Group 2 - Among the top ten circulating shareholders of Eddie Pharmaceuticals, the Xingsheng Global Fund has a fund that entered the top ten in the third quarter, holding 6.229 million shares, which accounts for 1.48% of the circulating shares [2] - The estimated floating profit for today is approximately 6.7273 million CNY, with a total floating profit of 25.4142 million CNY during the three-day increase [2] - The Xingsheng Global Fund's mixed fund (LOF) A (163415) was established on December 18, 2012, with a latest scale of 14.567 billion CNY, yielding 6.54% this year, ranking 2504 out of 8847 in its category, and 48.84% over the past year, ranking 2241 out of 8094 [2]

Core Viewpoint - Heng Rui Medicine's stock price has shown fluctuations, with a recent decline of 2.01% and a year-to-date increase of 3.91% [1][2]. Company Overview - Heng Rui Medicine, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology [2]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, addressing various diseases such as autoimmune, metabolic, cardiovascular, infectious, respiratory, hematological, pain management, neurological, ophthalmic, and renal diseases [2]. - The main revenue sources are 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2]. Financial Performance - For the period from January to September 2025, Heng Rui Medicine achieved a revenue of 23.188 billion yuan, representing a year-on-year growth of 14.85%, and a net profit attributable to shareholders of 5.751 billion yuan, with a year-on-year increase of 24.50% [3]. - The company has distributed a total of 9.303 billion yuan in dividends since its A-share listing, with 3.568 billion yuan distributed in the last three years [4]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 397,300, with an average of 16,058 circulating shares per person, a decrease of 8.21% from the previous period [3]. - Major shareholders include Hong Kong Central Clearing Limited, holding 487 million shares, and China Securities Finance Corporation, holding 95.4 million shares, with some reductions in holdings noted [4].

Core Viewpoint - XinNuoWei (300765) is expected to report a significant net profit loss for the year 2025, indicating a substantial decline compared to the previous year [1] Financial Performance - The company anticipates a net profit loss ranging from 170 million to 255 million yuan for 2025, representing a year-on-year decline of 416% to 575% [1] - Excluding non-recurring gains and losses, the expected net profit loss is projected to be between 210 million and 315 million yuan, reflecting a year-on-year decrease of 596% to 844% [1]

Group 1 - Garden Biologics experienced a stock price increase of 3.57% on January 15, with a trading volume of 828 million yuan [1] - The company had a net financing buy of -2.61 million yuan on the same day, with a total financing and margin balance of 732 million yuan [1] - The financing balance of Garden Biologics is 730 million yuan, accounting for 8.13% of its circulating market value, which is above the 80th percentile level over the past year [1] Group 2 - As of December 31, the number of shareholders for Garden Biologics was 26,200, a decrease of 12.35% from the previous period [2] - For the period from January to September 2025, the company reported a revenue of 936 million yuan, a year-on-year decrease of 0.20%, and a net profit attributable to shareholders of 234 million yuan, down 3.07% year-on-year [2] - The company has distributed a total of 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed in the last three years [2]

Group 1 - Two A-shares are set for equity registration today, with both companies planning to distribute dividends [1] - The dividend registration date for the two stocks is January 16, with Vision Intelligence and Aladdin offering the highest dividends of 3.00 yuan and 0.70 yuan per 10 shares, respectively [1] - Additionally, three other stocks have announced dividend distribution plans, with Life Pharmaceutical and Tianshan Aluminum proposing the highest dividends of 3.0 yuan and 1.0 yuan per 10 shares, respectively [1]

Core Viewpoint - The company, Hanyu Pharmaceutical (300199.SZ), has signed a sales order with a client for the procurement of GLP-1 active pharmaceutical ingredients amounting to 180 million RMB [1] Group 1 - The total procurement amount for the GLP-1 active pharmaceutical ingredients is 180 million RMB [1]

Core Viewpoint - The company, Yaoshi Technology (300725), announced the approval of several resolutions during its fourth board meeting, including changes to the use of raised funds and the establishment of a special fund account [1] Group 1 - The company approved a resolution to change the use of part of the raised funds and to add new investment projects [1] - The company authorized the opening of a special fund account and the signing of a regulatory agreement for the management of the raised funds [1] - The company also approved a resolution to change its registered capital and amend its articles of association, along with authorization for business registration changes [1]

金石亚药公告，全资子公司近日取得高新技术企业证书和专精特新中小企业证书。这标志着子公司在技 术创新和专业化发展方面得到认可，有助于提升公司的市场竞争力和品牌影响力。 ...